Autism - Pipeline Review, H2 2018 - Therapeutic Analysis of 22 Companies & Drug Profiles - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Autism - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Autism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 21, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction

2. Tourette Syndrome - Overview

3. Tourette Syndrome - Therapeutics Development

4. Tourette Syndrome - Therapeutics Assessment

5. Tourette Syndrome - Companies Involved in Therapeutics Development

6. Tourette Syndrome - Drug Profiles

7. Tourette Syndrome - Dormant Projects

8. Tourette Syndrome - Discontinued Products

9. Tourette Syndrome - Product Development Milestones

10. Appendix

Companies Featured

4D Pharma PLC AgeneBio Inc APeT Holding BV Bantam Pharmaceutical LLC BioHealthonomics Inc BrainStorm Cell Therapeutics Inc Coronis NeuroSciences Ltd Curemark LLC Evgen Pharma Plc F. Hoffmann-La Roche Ltd GW Pharmaceuticals Plc Heptares Therapeutics Ltd Immuron Ltd Intra-Cellular Therapies Inc Leading BioSciences Inc MedDay SA Omeros Corp OptiNose US Inc Ovensa Inc RespireRx Pharmaceuticals Inc Reviva Pharmaceuticals Inc Sumitomo Chemical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/24swvx/autism_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006116/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 03:28 PM/DISC: 09/25/2018 03:28 PM


Update hourly